var data={"title":"Tobramycin (systemic): Drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tobramycin (systemic): Drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/788626?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tobramycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tobramycin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=tobramycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tobramycin (systemic): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031119\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ototoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxicity, manifested as both auditory and vestibular ototoxicity, can occur. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Eighth nerve impairment and nephrotoxicity may develop, primarily in patients having preexisting renal damage and in those with healthy renal function to whom aminoglycosides are administered for longer periods or in higher doses than those recommended. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of aminoglycoside-induced hearing loss increases with the degree of exposure to either high peak or high trough serum concentrations. Patients who develop cochlear damage may not have symptoms during therapy to warn them of eighth-nerve toxicity, and partial or total irreversible bilateral deafness may continue to develop after the drug has been discontinued. Keep patients treated with tobramycin injection and other aminoglycosides under close clinical observation because these drugs have an inherent potential for causing ototoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Rarely, nephrotoxicity may not become apparent until the first few days after cessation of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible. Keep patients treated with tobramycin injection and other aminoglycosides under close clinical observation because these drugs have an inherent potential for causing nephrotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor renal and eighth nerve function in patients with known or suspected renal impairment and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Periodically monitor peak and trough serum concentrations of aminoglycosides during therapy to assure adequate levels and to avoid potentially toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided. Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such accumulation, excessive peak concentrations, advanced age, and cumulative dose may contribute to ototoxicity and nephrotoxicity. Examine urine for decreased specific gravity and increased excretion of protein, cells, and casts. Periodically measure serum urea nitrogen (BUN), serum creatinine, and creatinine clearance. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of impairment of renal, vestibular, or auditory function requires discontinuation of the drug or dosage adjustment.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use tobramycin injection with caution in premature and neonatal infants because of their renal immaturity and the resulting prolongation of serum half-life of the drug.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid concurrent and sequential use of other neurotoxic or nephrotoxic antibiotics, particularly other aminoglycosides (eg, amikacin, streptomycin, neomycin, kanamycin, gentamicin, paromomycin), cephaloridine, viomycin, polymyxin B, colistin, cisplatin, and vancomycin. Other factors that may increase patient risk are advanced age and dehydration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not give aminoglycosides concurrently with potent diuretics, such as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity, and intravenously (IV) administered diuretics enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides can cause fetal harm when administered to a pregnant woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031128\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>JAMP-Tobramycin;</li>\n      <li>Tobramycin For Injection;</li>\n      <li>Tobramycin For Injection, USP;</li>\n      <li>Tobramycin Injection;</li>\n      <li>Tobramycin Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031131\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Aminoglycoside</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031167\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Individualization is <b>critical</b> because of the low therapeutic index.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>In underweight and nonobese patients, use of total body weight (TBW) instead of ideal body weight for determining the initial mg/kg/dose is widely accepted (Nicolau 1995). Ideal body weight (IBW) also may be used to determine doses for patients who are neither underweight nor obese (Gilbert 2009). </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Initial and periodic plasma drug levels (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically-ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Severe life-threatening infections:</b>   IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conventional:</i> 1 to 2.5 mg/kg/dose every 8 to 12 hours; to ensure adequate peak concentrations early in therapy, higher initial dosage may be considered in selected patients when extracellular water is increased (edema, septic shock, postsurgical, and/or trauma)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Once-daily:</i> 4 to 7 mg/kg/dose once daily; some clinicians recommend this approach for all patients with normal renal function; this dose is at least as efficacious with similar, if not less, toxicity than conventional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brucellosis:</b> IM, IV: 240 mg (IM) daily or 5 mg/kg (IV) daily for 7 days; either regimen recommended in combination with doxycycline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholangitis:</b> IM, IV: 4 to 6 mg/kg once daily with ampicillin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS shunt infection:</b> Intrathecal (off-label route): 5 to 20 mg/day (Tunkel, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diverticulitis, complicated:</b> IM, IV: 1.5 to 2 mg/kg every 8 hours (with ampicillin and metronidazole)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis</b>  <b><i>(Enterococcus or Pseudomonas aeruginosa)</i></b>:  IV: 5 mg/kg/day in divided doses every 8 hours (administered with another bacteriocidal drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease:</b> IM, IV: Loading dose: 2 mg/kg, then 1.5 mg/kg every 8 hours <b>or</b> 4.5 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague</b> <b><i>(Yersinia pestis):</i></b> IM, IV: Treatment: 5 mg/kg/day, followed by postexposure prophylaxis with doxycycline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, hospital-acquired or ventilator-associated</b>: IV: 5 to 7 mg/kg/day once daily for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against <i>S. aureus</i> and an additional antipseudomonal agent. <b>Note: </b>Aminoglycosides are not recommended as monotherapy in patients with hospital-acquired or ventilator-associated pneumonia due to <i>P. aeruginosa</i> (Kalil 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against endocarditis (dental, oral, upper respiratory procedures, GI/GU procedures):</b> IM, IV: 1.5 mg/kg with ampicillin (50 mg/kg) 30 minutes prior to procedure. <b>Note:</b> AHA guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tularemia:</b> IM, IV: 5 mg/kg/day divided every 8 hours for 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection:</b> IM, IV: 1.5 mg/kg/dose every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031166\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tobramycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tobramycin (systemic): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Individualization is <b>critical</b> because of the low therapeutic index</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Use of ideal body weight (IBW) for determining the mg/kg/dose appears to be more accurate than dosing on the basis of total body weight (TBW).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Usual dosage range:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;5 years: 2.5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;5 years: 2 to 2.5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS shunt infection:</b> Intrathecal (off-label route): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis:</b> IM, IV: 2.5 to 3.3 mg/kg every 6 to 8 hours. <b>Note:</b> Some patients may require larger or more frequent doses if serum levels document the need (eg, cystic fibrosis or febrile granulocytopenic patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label):</b> Children and Adolescents: IV: 3 to 6 mg/kg/<b>day</b> divided every 8 hours; use in combination with other antibiotics dependent upon organism and source of infection (ie, valve-type) (AHA [Baltimore 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031168\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage should be based on an estimate of ideal body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM, IV: 1.5 to 5 mg/kg/day in 1 to 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Once daily or extended interval: 5 to 7 mg/kg/dose given every 24, 36, or 48 hours based on creatinine clearance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031169\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conventional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: Administer every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 40 to 60 mL/minute: Administer every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 39 mL/minute: Administer every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;20 mL/minute: Loading dose, then monitor levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High-dose therapy: Interval may be extended (eg, every 48 hours) in patients with moderate renal impairment (CrCl 30 to 59 mL/minute) and/or adjusted based on serum level determinations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz 2009): Dialyzable (25% to 70%; variable; dependent on filter, duration, and type of HD): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose of  2 to 3 mg/kg, followed by:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild UTI or synergy: 1 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD or post-HD serum concentrations &lt;1 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe UTI: 1 to 1.5 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD serum concentrations &lt;1.5 to 2 mg/L or post-HD concentrations &lt;1 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Systemic gram-negative infection: 1.5 to 2 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD serum concentrations &lt;3 to 5 mg/L or post-HD serum concentrations &lt;2 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis (PD):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administration via peritoneal dialysis (PD) fluid:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gram-negative infection: 4 to 8 mg/L (4 to 8 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gram-positive infection (ie, synergy): 3 to 4 mg/L (3 to 4 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administration IVPB/IM: Dose as for CrCl &lt;10 mL/minute and follow levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as target drug concentrations (if appropriate). <b>Note:</b> The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH/CVVHD/CVVHDF: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild UTI or synergy: Loading dose of 2 to 3 mg/kg, followed by 1 mg/kg/dose every 24 to 36 hours (redose when serum concentration &lt;1 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate-severe UTI: Loading dose of 2 to 3 mg/kg, followed by 1 to 1.5 mg/kg/dose every 24 to 36 hours (redose when serum concentration &lt;1.5 to 2 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Systemic gram-negative infection: Loading dose of 2 to 3 mg/kg, followed by 1.5 to 2.5 mg/kg/dose every 24 to 48 hours (generally accepted to redose when serum concentration &lt;2 mg/L; one reference suggests redosing when &lt;3 mg/L [Heintz 2009])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031170\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; does not undergo hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031171\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">In moderate obesity (TBW/IBW &ge;1.25) or greater, (eg, morbid obesity [TBW/IBW &gt;2]), initial dosage requirement may be estimated using a dosing weight of IBW + 0.4 (TBW - IBW) (Traynor 1995). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031190\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL); 80 mg/2 mL (2 mL); 1.2 g/30 mL (30 mL); 2 g/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg (100 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031130\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031174\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer by intermittent infusion over 20 to 60 minutes; higher doses are generally administered over 60 minutes (Aminimanizani 2002; Demsczar 1997). Flush line with saline before and after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031135\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of documented or suspected infections caused by susceptible gram-negative bacilli, including <i>Pseudomonas aeruginosa</i>. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031136\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Synergy (for gram-positive infections)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031120\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobramycin may be confused with Trobicin, vancomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebcin [Multiple international markets] may be confused with Naprosyn brand name for naproxen [US, Canada, and multiple international markets]; Nubain brand name for nalbuphine [Multiple international markets]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031146\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, disorientation, dizziness, headache, lethargy, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Exfoliative dermatitis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum calcium, decreased serum magnesium, decreased serum potassium, decreased serum sodium, increased lactate dehydrogenase, increased nonprotein nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Casts in urine, oliguria, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, eosinophilia, granulocytopenia, leukocytosis, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Auditory ototoxicity, hearing loss, tinnitus, vestibular ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, <i>clostridium difficile</i> associated diarrhea, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031143\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031144\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis: May cause neuromuscular blockade, respiratory failure, and prolonged respiratory paralysis, especially when given soon after anesthesia or muscle relaxants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity;</b> usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age, and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Tinnitus and/or hearing loss have also been reported. Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypocalcemia: Use with caution in patients with hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required during systemic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warnings]: Aminoglycosides may cause fetal harm if administered to a pregnant woman. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfite: Solution for injection may contain sodium metabisulfate; use caution in patients with sulfite allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Long-term use: Systemic therapy is not intended for long-term therapy due to toxic hazards associated with extended administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031205\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031202\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104955&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031138\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031139\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.</b> Tobramycin crosses the placenta. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of tobramycin may be altered (Bourget 1991). Tobramycin injection may be used for the management of cystic fibrosis in pregnant patients with <i>Pseudomonas aeruginosa</i> (inhalation is preferred unless risk of infection is great) (Edenborough 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031142\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tobramycin is found in breast milk following injection (Festini 2006; Uwaydah 1975).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As a class, aminoglycosides are expected to be poorly distributed into breast milk, limiting systemic exposure to a nursing infant. In general, modification of bowel flora may occur with any antibiotic exposure (Chung 2002). Based on low serum concentrations and low absorption, breast-feeding is generally considered compatible in women using tobramycin for the management of cystic fibrosis (Edenborough 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031173\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May require supplementation of calcium, magnesium, potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031178\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinalysis, urine output, BUN, serum creatinine, peak and trough plasma tobramycin levels. Levels are typically obtained after the third dose in conventional dosing. Be alert to ototoxicity; hearing should be tested before and during treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillin derivatives may accelerate the degradation of aminoglycosides in vitro. This may be clinically-significant for certain penicillin (ticarcillin, piperacillin, carbenicillin) and aminoglycoside (gentamicin, tobramycin) combination therapy in patients with significant renal impairment. Close monitoring of aminoglycoside levels is warranted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031154\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;\">Conventional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour following IM injection or beginning of infusion; draw trough immediately before next dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic levels:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serious infections: 6 to 8 mcg/mL (SI: 13 to 17 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Life-threatening infections: 8 to 10 mcg/mL (SI: 17 to 21 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Urinary tract infections: 4 to 6 mcg/mL (SI: 9 to 13 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infective endocarditis (<i>Pseudomonas aeruginosa</i>): 15 to 20 mcg/mL (SI: 32 to 43 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trough:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serious infections: 0.5 to 1 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Life-threatening infections: 1 to 2 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The American Thoracic Society (ATS) recommends trough levels of &lt;1 mcg/mL for patients with hospital-acquired pneumonia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monitor serum creatinine and urine output; obtain drug levels after the third dose unless otherwise directed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031152\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, resulting in a defective bacterial cell membrane</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031155\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Poorly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: DIstributes to extracellular fluid, including serum, abscesses, ascitic, pericardial, pleural, synovial, lymphatic, and peritoneal fluids; poor penetration into CSF, eye, bone, prostate; V<sub>d</sub>: Higher in neonates than older pediatric and adult patients; also increased in patients with edema, ascites, fluid overload; decreased in patients with dehydration; Systemic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 0.45 &plusmn; 0.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 0.4 &plusmn; 0.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 0.35 &plusmn; 0.15 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 0.3 &plusmn; 0.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.2 to 0.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: &le;1,200 g: 11 hours; &gt;1,200 g: 2 to 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 4 &plusmn; 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 2 &plusmn; 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 1.5 &plusmn; 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: IV: 2 to 3 hours; directly dependent upon glomerular filtration rate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults with impaired renal function: 5 to 70 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 30 to 60 minutes; IV: ~30 minutes; <b>Note:</b> Distribution may be prolonged after larger doses. One study reported a 1.7-hour distribution period after a 60-minute, high-dose aminoglycoside infusion (Demczar 1997). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Normal renal function: Urine (~90% to 95%) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031194\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tobramycin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g/30 mL (30 mL): $27.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (50 mL): $49.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $4.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/2 mL (2 mL): $2.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tobramycin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g (1): $93.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649945\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bactob (IN);</li>\n      <li>Brulamycin (HU);</li>\n      <li>Intolacin (VN);</li>\n      <li>Jiu Tai (CN);</li>\n      <li>Nebcin (AE, EG, PK, VN);</li>\n      <li>Nebcina (DK, NO);</li>\n      <li>Nebcine (FR);</li>\n      <li>Obracin (BE, CH);</li>\n      <li>Rui Nuo Sai (CN);</li>\n      <li>Tobra (KR);</li>\n      <li>Tobra-Day (AU, NZ);</li>\n      <li>Tobra-gobens (ES);</li>\n      <li>Tobracin (EG, JO);</li>\n      <li>Tobrasik (AT);</li>\n      <li>Tobrin (EG, QA);</li>\n      <li>Tocin (PK);</li>\n      <li>Tofib (AR);</li>\n      <li>Tomycin (FI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 2002;50(4):553-559.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/12356801/pubmed\" target=\"_blank\" id=\"12356801\">12356801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer LA and Blouin RA, &ldquo;Influence of Age on Tobramycin. Pharmacokinetics in Patients With Normal Renal Function,&rdquo; <i>Antimicrob Agents Chemother</i>, 1981, 20:587-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/7325627/pubmed\" target=\"_blank\" id=\"7325627\">7325627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Delouis C, et al, &quot;Pharmacokinetics of Tobramycin in Pregnant Women. Safety and Efficacy of a Once-Daily Dose Regimen,&quot; <i>J Clin Pharm Ther</i>, 1991, 16(3):167-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/1869596/pubmed\" target=\"_blank\" id=\"1869596\">1869596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani, and Nightingale CH, &quot;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&quot; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &quot;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demczar DJ, Nafziger AN, and Bertino JS Jr, &quot;Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing,&quot; <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1115-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/9145878/pubmed\" target=\"_blank\" id=\"9145878\">9145878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &quot;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&quot; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(Suppl 1):S2-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/18024241 /pubmed\" target=\"_blank\" id=\"18024241 \">18024241 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Festini F, Ciuti R, Taccetti G, et al, &quot;Breast-Feeding in a Woman With Cystic Fibrosis Undergoing Antibiotic Intravenous Treatment,&quot; <i>J Matern Fetal Neonatal Med</i>, 2006, 19(6):375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/16801316/pubmed\" target=\"_blank\" id=\"16801316\">16801316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN and Leggett JE, &ldquo;Aminoglycosides,&rdquo; <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases,</i> 7th ed, Chapter 26, Mandell GL, Bennett JE, and Dolin R, eds, Philadelphia, PA: Churchill Linvingstone Elsevier, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, &ldquo;Once-Daily Aminoglycoside Therapy,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(3):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/2039189/pubmed\" target=\"_blank\" id=\"2039189\">2039189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green TP, Mirkin BL, Peterson PK, et al, &ldquo;Tobramycin Serum Level Monitoring in Young Patients With Normal Renal Function,&rdquo; <i>Clin Pharmacokinet</i>, 1984, 9(5):457-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/6499344/pubmed\" target=\"_blank\" id=\"6499344\">6499344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &quot;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hustinx WN and Hoepelman IM, &ldquo;Aminoglycoside Dosage Regimens. Is Once a Day Enough?&rdquo; <i>Clin Pharmacokinet</i>, 1993, 25(6):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/8119044/pubmed\" target=\"_blank\" id=\"8119044\">8119044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaffe G, Meyers BR, and Hirschman SZ, &ldquo;Pharmacokinetics of Tobramycin in Patients With Stable Renal Impairment, Patients Undergoing Peritoneal Dialysis, and Patients on Chronic Hemodialysis,&rdquo; <i>Antimicro Agents Chemother</i>, 1974, 5(6):611-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/15825414/pubmed\" target=\"_blank\" id=\"15825414\">15825414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matzke GR, Jameson JJ, and Halstenson CE, &ldquo;Gentamicin Disposition in Young and Elderly Patients With Various Degrees of Renal Function,&rdquo; <i>J Clin Pharmacol</i>, 1987, 27(3):216-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/3680577/pubmed\" target=\"_blank\" id=\"3680577\">3680577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer PR, Brown CH, Carter RA, et al, &ldquo;Intramuscular Tobramycin Pharmacokinetics in Geriatric Patients,&rdquo; <i>Drug Intell Clin Pharm</i>, 1986, 20:611-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/3743420/pubmed\" target=\"_blank\" id=\"3743420\">3743420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCormack JP and Jewesson PJ, &ldquo;A Critical Re-evaluation of the &ldquo;Therapeutic Range&rdquo; of Aminoglycosides,&rdquo; <i>Clin Infect Dis</i>, 1992, 14(1):320-39.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Powell DA, Durrell DE, et al, &ldquo;Effect of Gestational Age and Birth Weight on Tobramycin Kinetics in Newborn Infants,&rdquo; <i>J Antimicrob Chemother</i>, 1984, 14(1):59-65.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, Freeman CD, Belliveau PP, et al, &ldquo;Experience With a Once-Daily Aminoglycoside Program Administered to 2184 Adult Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(3):650-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/7793867/pubmed\" target=\"_blank\" id=\"7793867\">7793867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preston SL and Briceland LL, &ldquo;Single Daily Dosing of Aminoglycosides,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(3):297-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/7667165/pubmed\" target=\"_blank\" id=\"7667165\">7667165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rybak MJ, Boike SC, Levine DP, Erickson SR. Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. <i>J Antimicrob Chemother</i>. 1986;17(1):115-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/3949634/pubmed\" target=\"_blank\" id=\"3949634\">3949634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith PF, Ballow CH, Booker BM, et al, &quot;Pharmacokinetics and Pharmacodynamics of Aztreonam and Tobramycin in Hospitalized Patients,&quot; <i>Clin Ther</i>, 2001, 23(8):1231-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/11558860/pubmed\" target=\"_blank\" id=\"11558860\">11558860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobramycin (tobramycin sulfate injection solution) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Traynor AM, Nafziger AN, and Bertino JS Jr, &ldquo;Aminoglycoside Dosing Weight Correction Factors for Patients of Various Body Sizes,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(2):545-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/7726530/pubmed\" target=\"_blank\" id=\"7726530\">7726530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uwaydah M, Bibi S, and Salman S, &quot;Therapeutic Efficacy of Tobramycin - A Clinical and Laboratory Evaluation,&quot; <i>J Antimicrob Chemother</i>, 1975, 1(4):429-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-drug-information/abstract-text/1107297/pubmed\" target=\"_blank\" id=\"1107297\">1107297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104955 Version 58.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F45031119\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45031128\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45031131\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45031167\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45031166\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45031168\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45031169\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45031170\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F45031171\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45031190\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45031130\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45031174\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45031135\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45031136\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45031120\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45031146\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45031143\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45031144\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45031205\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45031202\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45031138\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45031139\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45031142\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F45031173\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45031178\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F45031154\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45031152\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45031155\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45031194\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45649945\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104955|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tobramycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Tobramycin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=tobramycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Tobramycin (systemic): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}